Literature DB >> 10914483

CXC chemokines in angiogenesis.

J A Belperio1, M P Keane, D A Arenberg, C L Addison, J E Ehlert, M D Burdick, R M Strieter.   

Abstract

A variety of factors have been identified that regulate angiogenesis, including the CXC chemokine family. The CXC chemokines are a unique family of cytokines for their ability to behave in a disparate manner in the regulation of angiogenesis. CXC chemokines have four highly conserved cysteine amino acid residues, with the first two cysteine amino acid residues separated by one non-conserved amino acid residue (i.e., CXC). A second structural domain within this family determines their angiogenic potential. The NH2 terminus of the majority of the CXC chemokines contains three amino acid residues (Glu-Leu-Arg: the ELR motif), which precedes the first cysteine amino acid residue of the primary structure of these cytokines. Members that contain the ELR motif (ELR+) are potent promoters of angiogenesis. In contrast, members that are inducible by interferons and lack the ELR motif (ELR-) are potent inhibitors of angiogenesis. This difference in angiogenic activity may impact on the pathogenesis of a variety of disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914483

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  228 in total

Review 1.  Molecular machinations: chemokine signals in host-pathogen interactions.

Authors:  S W Chensue
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Enhancing antitumor immunity perioperatively: a matter of timing, cooperation, and specificity.

Authors:  Jeffrey L Curtis; Antonello Punturieri
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05       Impact factor: 6.914

Review 3.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

4.  Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing.

Authors:  Karri Paavonen; Niklas Ekman; Maria Wirzenius; Iiro Rajantie; Matti Poutanen; Kari Alitalo
Journal:  Mol Biol Cell       Date:  2004-06-30       Impact factor: 4.138

Review 5.  Muscles, exercise and obesity: skeletal muscle as a secretory organ.

Authors:  Bente K Pedersen; Mark A Febbraio
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

6.  Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors.

Authors:  Prem Raj B Joseph; Jose M Sarmiento; Anurag K Mishra; Sandhya T Das; Roberto P Garofalo; Javier Navarro; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2010-07-14       Impact factor: 5.157

7.  The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.

Authors:  Keiji Tanese; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

8.  Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy.

Authors:  Francesca Gotsch; Roberto Romero; Jimmy Espinoza; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Offer Erez; Nandor Gabor Than; Samuel Edwin; Moshe Mazor; Bo Hyan Yoon; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-10

Review 9.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

10.  In vitro cytokine release profile: predictive value for metastatic potential in head and neck squamous cell carcinomas.

Authors:  Omar Shkeir; Maria Athanassiou-Papaefthymiou; Martian Lapadatescu; Petros Papagerakis; Michael J Czerwinski; Carol R Bradford; Thomas E Carey; Mark E P Prince; Gregory T Wolf; Silvana Papagerakis
Journal:  Head Neck       Date:  2013-01-16       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.